BioCentury
ARTICLE | Clinical News

Corluxin mifepristone regulatory update

November 11, 2013 8:00 AM UTC

Corcept disclosed in its 3Q13 earnings that it submitted an MAA to EMA for Corluxin mifepristone to treat endogenous Cushing's syndrome. Corcept expects feedback from EMA in 1Q14. Corcept markets the ...